HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Background:

Hepatic arterial infusion chemotherapy (HAIC) and Transarterial chemoembolization (TACE) both showed good local efficacy in advanced or unresectable hepatocellular carcinoma (HCC). We performed a systematic review and meta-analysis to compare the effect of HAIC with TACE in patients with unresectable HCC.

Methods:

Clinical trials, which were about HAIC or TACE in Patients with unresectable HCC, were identified by searching PubMed, Medline, and EMBASE from January 2010 to March 2022. A meta-analysis was performed to analyze HAIC in comparison with TACE. Treatment response, 1-year overall survival (OS), 2-year OS and serious adverse events were evaluated in this meta-analysis.

Results:

This meta-analysis included 6 studies. Objective response rate or Partial response in the HAIC group was significantly more than that in the TACE group ( P < .05). But, stable disease showed no difference between the 2 groups ( P = .52). Disease control rate in the HAIC group was better than that in the TACE group ( P < .05). Progressive disease in the HAIC group was less than that in the TACE group ( P < .05). In 1-year OS, there was no significant deterioration between the 2 groups ( P = .53). There was not significant difference in 2-year OS between the 2 groups ( P = .05). serious adverse events in the HAIC group was significantly less than that in the TACE group ( P < .05).

Conclusion:

To some degree, HAIC may be a better therapeutic method in patients with unresectable HCC than TACE.

Related collections

Most cited references 36

Record: found
Abstract: found
Article: not found

Cancer statistics in China, 2015.

Wanqing Chen, Rongshou Zheng, Peter D Baade … (2016)

With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.

0 comments Cited 4366 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Valérie Vilgrain, Peter Galle, Alejandro Forner … (2018)

0 comments Cited 2600 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata, Ann-Lii Cheng, Norihiro Kokudo … (2017)

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

0 comments Cited 648 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Jinjuan Zhang

Guiming Shu

Cheng Lou

Zhi Du

Journal

Journal ID (nlm-ta): Medicine (Baltimore)

Journal ID (iso-abbrev): Medicine (Baltimore)

Journal ID (publisher-id): MD

Title: Medicine

Publisher: Lippincott Williams & Wilkins (Hagerstown, MD )

ISSN (Print): 0025-7974

ISSN (Electronic): 1536-5964

Publication date (Electronic): 23 December 2022

Publication date Collection: 23 December 2022

Volume: 101

Issue: 51

Electronic Location Identifier: e32390

Affiliations

[a ] The Third Central Hospital of Tianjin (The Third Central Clinical College of Tianjin Medical University), Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin, China.

Author notes

* Correspondence: Junguo Liu, The Third Central Hospital of Tianjin, No.83 Jintang Road, Hedong District, Tianjin China (e-mail: liujunguo1999@ 123456aliyun.com ).

Article

Accession ID: 00080

DOI: 10.1097/MD.0000000000032390

PMC ID: 9794325

PubMed ID: 36595819

SO-VID: c93feb9b-4507-4132-8d5e-b0926c4a947e

License:

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

History

Date received : 13 June 2022

Date received : 2 December 2022

Date accepted : 2 December 2022

Custom metadata

OPEN-ACCESS TRUE

Keywords: hepatic arterial infusion chemotherapy,transarterial chemoembolization,unresectable hepatocellular carcinoma

Data availability:

Keywords: hepatic arterial infusion chemotherapy, transarterial chemoembolization, unresectable hepatocellular carcinoma

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Read this article at

Background:

Methods:

Results:

Conclusion:

Related collections

Hogrefe Medicine

Most cited references 36

Cancer statistics in China, 2015.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Categories

Custom metadata

Comments

Comment on this article

Similar content 1,287

Cited by 8

Most referenced authors 1,150